The Presence Study- Studying the Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD)
The purpose of this study is to determine how LY3154207 compares with placebo in treating memory and thinking problems in individuals with mild-to-moderate Parkinson?s disease dementia.
The primary objective is to test the hypothesis that LY3154207 administered at 10 mg, 30 mg, and/or 75 mg daily (or 50 mg based on interim analysis) (QD) oral dosing for 12 weeks will result in significant improvement in cognition in subjects with mild-to-moderate Parkinson's Disease Dementia (PDD) compared with placebo.
Participants will be paid for their participation.
- IRB Number: 1709267154
- Research Study Identifier: TX8499
- Principal Investigator: Jared Brosch, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required